Apixaban safer than rivaroxaban in AF with liver disease, doctors say
Doctors can be reassured that apixaban is safe for patients with AF and liver disease, a retrospective cohort study suggests. The Harvard University-led study found…
Doctors can be reassured that apixaban is safe for patients with AF and liver disease, a retrospective cohort study suggests. The Harvard University-led study found…
Patients prescribed extended anticoagulation for VTE have a lower risk of recurrent VTE with NOACs compared to warfarin, according to a study in JAMA Network…
Australian study shows AF patients on NOACs are less likely to experience cognitive decline than those on warfarin.
The combination of drugs is common and there is a dose-response relationship, researchers say.
New results from the VOYAGER PAD trial shows a benefit with no increase in bleeds.
Patients are missing out on timely review of their stroke risk in primary care, a study suggests.
The analysis in people with AF suggests a NOAC might be the better option for those at risk of osteoarthritis, authors say.
Emerging evidence suggests patients with AF who have a bleed should probably be investigated for malignancy, cardiologists warn.
A secondary trial analysis shows low-dose rivaroxaban and aspirin benefit high-risk patients with lower extremity PAD, authors say.
Choosing between the two drugs is a choice between thrombotic or haemorrhagic risk.
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.